INTRODUCTION
============

Diabetes is becoming a global health problem. As estimated by International Diabetes Federation [@B1], there were 366 million people suffering from diabetes worldwide in 2011, and by 2030 this figure will rise to 552 million. Diabetes also caused 4.6 million deaths and at least 465 billion US dollars in healthcare expenditures (11% of total healthcare expenditures in adults aged 20-79 years) in 2011 [@B1].

Despite the recent advocating of hemoglobin A1c (HbA1c) ≥ 6.5% as a diabetes diagnostic tool by several international diabetes associations [@B2],[@B3], for decades, the diagnosis of diabetes is mainly based on fasting plasma glucose (FPG) and/or 2-hour plasma glucose (2h-PG) after 75-g glucose challenge. As stated in the new diabetes guideline [@B2], the assay of HbA1c needs specially standardized and certified method. This technological-demanding will offset the high stability of HbA1c assay and will hinder its widespread use. On the other hand, the practical application of HbA1c as a diagnostic tool needs extensively verification in different countries with local diabetes epidemiological data, so does the determination of its optimal cut-off value. As a result, the introduction of HbA1c into diabetes diagnostic protocol demands a certain period of time, especially in developing countries such as China, where data are limited.

There are strong reasons for considering diabetes as a risk equivalent of coronary heart disease (CHD) [@B4]. The presence of diabetes is often labeled as high or very high risk in contemporary clinical practice [@B5], [@B6]. From this point of view, both HbA1c and oral glucose tolerance test (OGTT) are effective indicators for risk stratification. However, HbA1c and OGTT reflect different aspects of glucose metabolism. It raises the question whether HbA1c identifies different cardiovascular and metabolic risk profiles from OGTT. Several studies [@B7]-[@B10] have reported that diabetes diagnosed by HbA1c had higher body mass index (BMI), age, lipid levels or insulin resistance than those diagnosed by OGTT. To date, it remains unknown in Chinese diabetes population, the largest number in the world and manifesting postprandial hyperglycemia-oriented pattern [@B11], which is different from western counterparts [@B12]. Therefore, we designed the current survey to compare the difference of cardiovascular and metabolic risk profile between different HbA1c and glucose indicators category in a southern Chinese general population.

METHODS
=======

Study design and subjects
-------------------------

Subjects were recruited from general population of 17 villages in southern China. The inclusion criteria were indigenous adult aged more than or equal to 35 years. People with previously-diagnosed diabetes (PDD), acute illness, anemia history, or incomplete data were excluded. Finally, 6,540 subjects were recruited. A flow chart was presented as Figure [1](#F1){ref-type="fig"}. All participants provided written informed consent to participate in the study.

The study complied with the declaration of Helsinki. The study protocol was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University.

Questionnaire survey
--------------------

All participants completed a questionnaire, including items of demographic features, lifestyle, smoking and drinking habit, symptoms of hyperglycemia, family or personnel disease histories, especially CHD and related intervention (medicine and revascularization procedure), hypertension and antihypertensive drugs usage.

Anthropometric measurements
---------------------------

Anthropometric measurements were taken to obtain height, weight, waist circumference and hip circumference according to standard technique by trained investigators. Participants stood with bare feet close together, arms at the side and wore little clothing. Waist circumference was measured at the midpoint between the lower margin of the last rib and the top of the iliac crest. Hip circumference was measured around the widest portion of the buttocks, with the tape paralleled to the floor. Each measurement should be repeated twice. If the measurements were within 1 cm of one another, the average would be calculated. Otherwise, another two measurements should be repeated. Waist-hip ratio (WHR) was the ratio of the circumference of the waist to that of the hip. BMI was calculated by the participants\' body mass (kg) divided by the square of height (m^2^). According to Chinese diabetes guideline [@B13], obesity is defined as BMI ≥ 2428kg/m^2^and abdominal obesity is defined as waist circumference ≥ 90 cm in male or ≥ 85 cm in female.

Heart rate (HR) and blood pressure were recorded in all participants after rest for at least 5 minutes. Blood pressure was measured in the right arm in the sitting position with a mercury sphygmomanometer and proper bladder. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were identified by phase I and V (disappearance) Korotkoff sounds. Two measurements for each individual were taken with an interval of at least 1 minute. If the first two readings were quite different (≥ 5mmHg), an additional measurement was performed. The mean of these measurements was calculated and recorded. Hypertension was diagnosed as SBP ≥ 140mmHg and or DBP ≥ 90mmHg or on anti-hypertensive treatment.

Laboratory assay
----------------

All participants underwent FPG, 2h-PG, HbA1c, total cholesterol (TC), triglyceride, high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) measurement. The detection of FPG and lipid profile needed an overnight fasting. OGTT was carried out according to World Health Organization (WHO) standardized protocol [@B14]. Venous blood samples were collected into vacuum tubes containing ethylenediaminetetraacetic acid (EDTA). Plasma was collected and stored at -80°C until future detection. HbA1c test was performed with whole blood specimen at the day of blood collection. While other tests were performed collectively with stored plasma. Internal quality control was carried out at low, medium and high level every day before HbA1c assay. All tests follow manufacturers\' instructions. Room temperature and humidity were controlled at 15 - 20 °C and 50% - 60%, respectively.

HbA1c was assayed by ion-exchange high-performance liquid chromatography (D-10, Bio-Rad Laboratories, Hercules, CA, USA), which had been certified by National Glycohemoglobin Standardization Program (NGSP) and was traceable to the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reference method. Plasma glucose (FPG and 2h-PG) were measured by glucose oxidase-perioxidase method with TBA-120 auto-analyzer (Toshiba Medical Systems, Japan). TC (cholesterol oxidase-perioxidase aminopyrine method), triglyceride (glycerol phosphate oxidase-perioxidase aminopyrine method), HDL-C (direct method) and LDL-C (direct method) were measured using TBA-120 auto-analyzer (Toshiba Medical Systems, Japan).

Diabetes diagnosis
------------------

Currently, HbA1c is not accepted as a criterion for diabetes in China. As a result, all cases of newly-detected diabetes (NDD) were diagnosed by standard OGTT criteria according to American Diabetes Association (ADA) guideline [@B2]: FPG ≥ 7.0mmol/l (126mg/dl) or 2h-PG ≥ 11.1mmol/l (200 mg/dl) during an OGTT, in the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing.

Statistical analysis
--------------------

All statistical analyses were processed with SPSS 13.0 statistical package (SPSS, Inc., Chicago, IL). Continuous variables were expressed as mean ± standard deviation when in normal distribution, or median (P2.5-P97.5) in skewed distribution. Categorical variables were expressed as numbers and percentages. Receiver operating characteristic (ROC) curve was constructed to calculate sensitivity and specificity of HbA1c at 6.5% for diabetes diagnosis, using OGTT as the gold standard. The difference between participants with HbA1c ≥ 6.5% and HbA1c \< 6.5% in OGTT-negative group and OGTT-positive group was tested by t-test, nonparametric test, or Pearson Chi-square test according to the variable type and distribution. According to current guidelines [@B2], [@B4]-[@B6], blood pressure, plasma lipid and glucose levels were correlated with age, gender, current smoking and weight, as a result, analysis of covariance (ANCOVA) was used for correction when the differences of the latter were statistically significant. A two-tailed *P*value \<0.05 was considered to be statistically significant.

RESULTS
=======

General features
----------------

A total of 6,540 participants were recruited, with mean age 51 (36-80) years, and 40.6% of them were male. 422 participants were diagnosed as diabetes according to OGTT. The prevalence of OGTT-diagnosed diabetes was 6.45%. In these patients, 287 cases had their HbA1c level ≥ 6.5%. In 6,118 OGTT-negative participants, 190 cases had their HbA1c levels exceeded 6.5% (Figure [2](#F2){ref-type="fig"}). The sensitivity and specificity of HbA1c at 6.5% were 66.8% and 97.1%, respectively.

Comparison between HbA1c ≥ 6.5% and HbA1c \< 6.5% among OGTT-negative participants
----------------------------------------------------------------------------------

In contrast to subjects with HbA1c \< 6.5%, subjects with HbA1c ≥ 6.5% were older, had higher prevalence of CHD, current smoking, hypertension, obesity and abdominal obesity. They also had higher body weight, WHR, BMI, TC, LDL-C, FPG, 2h-PG and HbA1c than that of subjects with HbA1c \< 6.5%. No significant difference was shown in gender, SBP, DBP, HR, TG and HDL-C. (Table [1](#T1){ref-type="table"})

Comparison between HbA1c ≥ 6.5% and HbA1c \< 6.5% among OGTT-positive patients
------------------------------------------------------------------------------

Compared with patients of HbA1c \< 6.5%, patients with HbA1c ≥ 6.5% had higher body weight, Waist circumference, WHR, and higher concentration of TC, triglyceride, FPG, 2h-PG and HbA1c. But they were younger, had lower prevalence of hypertension than those of HbA1c \< 6.5%. The differences between gender, smoking rate, SBP, DBP, HR, LDL-C and HDL-C levels, and the prevalence of CHD, obesity yielded no statistically significant (Table [2](#T2){ref-type="table"}).

DISCUSSION
==========

Our study demonstrated that, compared with participants with HbA1c \< 6.5%, subjects with HbA1c ≥ 6.5% had more unfavorable cardiovascular and metabolic risk profiles, especially in OGTT-negative participants. Our results suggested that HbA1c could further stratify cardiovascular and metabolic risk beyond OGTT. More attention should be paid to those with HbA1c ≥ 6.5% but normal OGTT result in clinical practice. It was noteworthy that the difference of SBP between HbA1c ≥ 6.5% and HbA1c \< 6.5% in two groups (7mmHg and 6mmHg, respectively) were not statistically significant after adjustment. However, as stated by JNC-7 [@B15], death from both ischemic heart disease and stroke increases progressively and linearly from BP levels 115/75 mmHg upward. Furthermore, a meta-analysis from Blood Pressure Lowering Treatment Trialists\' Collaboration has demonstrated that 4-8 mmHg change in mean SBP is associated with decrease of major adverse cardiovascular events (stroke, CHD, heart failure, cardiovascular death and total mortality) [@B16]. So, the differences of SBP in our population are considered to be clinically important, although not statistically significant.

HbA1c and the traditional glucose indicators (FPG and 2h-PG) reflect different aspects of glucose metabolism, it is interesting to explore whether HbA1c identifies different cardiovascular and metabolic risk profiles from OGTT. Several studies have focused on the disparity between HbA1c and glucose indicators across several ethnic groups. But their studies had smaller scale than ours and were mostly post-hoc analysis. Boronat et al [@B7] researched into 964 individuals from Spain and reported that subjects with HbA1c ≥ 6.5% had higher values of BMI, waist circumference, FPG, fibrinogen and homeostasis model assessment of insulin resistance (HOMA-IR), but lower values for HDL-C. Kim et al [@B8] analyzed data of 1,491 Koreans, who were categorized by FPG (≥ 7.0mmol/L) and HbA1c (≥ 6.5%), and they found that HbA1c-diagnosed diabetes group had significantly older age, higher proportion of women, while FPG-diagnosed diabetes group had higher SBP or DBP, fasting serum insulin, and HOMA-IR. Another epidemiology survey [@B9] from South Korea reported that the discordance between the two diabetes criteria (HbA1c and FPG) was significantly associated with obesity and older age. The Guangdong Health Survey 2010 (GHS 2010) [@B10] involved 3,590 residents aged 18 years of age or above and found that, compared to diabetes diagnosed by glucose indicators, patients with HbA1c ≥ 6.5% were generally older, and had higher BMI, waist circumference, blood pressure, lipids (except for HDL-C) and insulin levels.

Our data also demonstrated that HbA1c identified more cardiovascular and metabolic risk than OGTT, especially in OGTT-negative group. In OGTT-negative group, subjects with HbA1c ≥ 6.5% were older, had higher prevalence of coronary heart disease, current smoking, hypertension, obesity and abdominal obesity. They also had higher body weight, waist-hip ratio, BMI, glucose levels (fasting plasma glucose, 2-hour plasma glucose and HbA1c), and lipid levels (total cholesterol and low density lipoprotein cholesterol). Our results are not exactly the same as other studies in risk profiles. Differences in ethnicity, dietary and hyperglycemia patterns, study population, study design and diagnostic criteria might be the reasons for the discrepancy of our data and the others. Several studies have demonstrated that HbA1c level may vary with patients\' ethnicity that are independent of glucose level [@B17], [@B18]. Bloomgarden et al [@B19] showed that almost 70% of the intra-individual hemoglobin glycation variation was assumed to be genetically pre-determined. Chinese feed on carbohydrate-enriched foods and demonstrate higher proportion of postprandial hyperglycemia compared with western people. As showed by national diabetes survey of China by Yang et al [@B11], 46.6% of the participants with newly-diagnosed diabetes had isolated high 2h-PG levels, comparing with only 29% in the European population [@B12]. Nevertheless, our data and the aforementioned studies demonstrate consistently that HbA1c identifies different cardiovascular and metabolic risk profile from FPG and 2h-PG.

Diabetes has been considered as a risk equivalent of CHD [@B4]. The presence of diabetes is often labeled as high or very high risk in contemporary clinical practice [@B5], [@B6]. As a result, the capacity of HbA1c to further identify high risk is reduced in this already high or very high risk population. More importantly, we expanded our research into OGTT-negative population and found that HbA1c ≥ 6.5% represented more unfavorable and significant cardiovascular and metabolic risk profile in this group. This finding underscores the feature of HbA1c in risk stratification in OGTT-negative population. That is, HbA1c can identify population with high cardiovascular and metabolic risk at an earlier stage than FPG and 2h-PG. As what has been proved by many surveys and clinical trials, the most benefit in diabetes management comes from early diagnosis and early treatment so as to prevent or delay the onset of costly and harmful complications. From this point of view, HbA1c may be a more suitable and practical diagnostic criterion for diabetes than FPG and 2h-PG.

The mechanism for HbA1c\'s better performance in risk stratification is not fully elucidated. HbA1c represents the average glucose level in the preceding 8-12 weeks. Therefore, HbA1c is a more stable indicator for glucose level in a certain period of time than FPG and 2h-PG. Several researches have reported that long-term poor glucose control is associated with endothelial dysfunction [@B20], [@B21], arterial stiffness [@B22], [@B23], low-grade systemic inflammation [@B24], oxidative stress [@B25], and platelet activation [@B26]. However, the exact mechanism may be multi-factorial and interactive, because the above-mentioned patho-physiological changes often coexist and interact with each other.

In conclusion, subjects with HbA1c ≥ 6.5% have more unfavorable cardiovascular and metabolic risks than those with HbA1c \< 6.5%, especially in OGTT-negative population. This has important clinical implication because it indicates that this subgroup (subjects with HbA1c ≥ 6.5% and normal OGTT) may not be at low risk as previously thought, and more intensive management should be employed. Further studies are required for the mechanism of the discrepancy of HbA1c in risk stratification of OGTT-negative and OGTT-positive population.
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![Flow chart of trial. NDD, newly-detected diabetes; PDD, previously-diagnosed diabetes. All cases of diabetes were diagnosed according to OGTT results.](ijmsv10p1028g01){#F1}

![Number of the patients identified by OGTT and HbA1c test. 422 participants were diagnosed as diabetes according to OGTT. In these patients, 287 cases had their HbA1c level more than or equal to 6.5%, and the remaining 135 patients had HbA1c level less than 6.5%. In the participants diagnosed as non-diabetes according to OGTT, 190 cases had their HbA1c levels exceeded 6.5%.](ijmsv10p1028g02){#F2}

###### 

Comparison between HbA1c ≥ 6.5% and HbA1c \< 6.5% in OGTT-negative group

  ------------------------------------------------------------------------
                             HbA1c \< 6.5%\    HbA1c ≥ 6.5%\     P value
                             (n=5928)          (n=190)           
  -------------------------- ----------------- ----------------- ---------
  Age, years                 50(36-79)         59(40-83)         0.000

  Male, %                    40.1(2376/5928)   42.6(81/190)      0.480

  CHD, %                     1.1(64/5928)      3.2(6/190)        0.008

  Smoking, %                 24.8(1472/5928)   36.8(70/190)      0.000

  **Anthropometric index**                                       

  Weight, kg                 60(42-84)         64(45-92)         0.000

  BMI, kg/m^2^               24.2(18.3-32.0)   26.6(18.5-33.7)   0.000

  BMI ≥ 24kg/m^2^, %         52.3(3091/5906)   71.4(135/189)     0.000

  Waist circumference, cm    81(65-100)        87(71-106)        0.000

  Hip circumference, cm      93(82-108)        96(83-112)        0.000

  WHR                        0.87(0.75-1.00)   0.90(0.78-1.05)   0.000

  Abdominal obesity, %       30.2(1769/5865)   40.6(76/187)      0.002

  **Hemodynamic index\***                                        

  SBP, mmHg                  128(102-174)      135(107-186)      0.897

  DBP, mmHg                  74(57-98)         75(60-102)        0.393

  HR, bpm                    80(61-108)        81(60-106)        0.999

  Hypertension, %            24.7(1464/5917)   36.5(69/189)      0.000

  **Lipid index\***                                              

  TC, mmol/L                 5.14(3.46-7.29)   5.61(3.29-7.93)   0.004

  TG, mmol/L                 1.20(0.50-3.94)   1.47(0.54-4.56)   0.169

  HDL-C, mmol/L              1.43(0.90-2.33)   1.40(0.85-2.07)   0.240

  LDL-C, mmol/L              3.05(1.29-4.93)   3.37(1.22-5.72)   0.002

  **Glucose index\***                                            

  FPG, mmol/L                5.4(4.5-6.6)      6.1(4.9-7.4)      0.000

  2h-PG, mmol/L              6.4(3.5-11.0)     8.0(3.8-13.5)     0.000

  HbA1c, %                   5.7(4.8-6.3)      6.6(6.5-7.4)      0.000
  ------------------------------------------------------------------------

BMI, body mass index; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HR, heart rate; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; WHR, waist-hip ratio; 2h-PG, 2-hour plasma glucose. \* adjusted by age, body weight, current smoking.

###### 

Comparison between HbA1c ≥ 6.5% and HbA1c \< 6.5% in OGTT-positive group

  -------------------------------------------------------------------------
                             HbA1c \< 6.5%\    HbA1c ≥ 6.5%\      P value
                             (n=135)           (n=287)            
  -------------------------- ----------------- ------------------ ---------
  Age, years                 60(38-88)         55(36-81)          0.002

  Male, %                    43.0(58/135)      48.8(140/287)      0.264

  CHD, %                     3.7(5/135)        1.7(5/287)         0.217

  Smoking, %                 30.4(41/135)      27.9(80/287)       0.597

  **Anthropometric index**                                        

  Weight, kg                 63.0(37.8-91.3)   66(46-94)          0.004

  BMI, kg/m^2^               26.1(18.4-33.8)   26.8(20.8-33.9)    0.078

  BMI ≥ 24kg/m2, %           71.6(96/134)      78.6(224/285)      0.118

  Waist circumference, cm    87(67-107)        89(72-108)         0.003

  Hip circumference, cm      96(82-112)        96(84-111)         0.176

  WHR                        0.90(0.73-1.03)   0.93(0.81-1.04)    0.003

  Abdominal obesity, %       36.6(49/134)      46.6(131/281)      0.053

  **Hemodynamic index\***                                         

  SBP, mmHg                  143(102-195)      137(109-188)       0.201

  DBP, mmHg                  81(58-104)        80(62-104)         0.702

  HR, bpm                    84(57-128)        85(63-115)         0.540

  Hypertension, %            59.0(79/134)      46.7(134/287)      0.019

  **Lipid index\***                                               

  TC, mmol/L                 5.28(3.07-7.95)   5.63(3.44-8.04)    0.005

  TG, mmol/L                 1.64(0.65-5.27)   1.95(0.72-10.70)   0.002

  HDL-C, mmol/L              1.31(0.86-1.97)   1.26(0.86-2.13)    0.806

  LDL-C, mmol/L              3.16(1.37-5.68)   3.32(1.15-5.30)    0.626

  **Glucose index\***                                             

  FPG, mmol/L                6.8(4.9-9.2)      8.5(6.2-20.6)      0.000

  2h-PG, mmol/L              12.2(6.6-18.2)    17.7(7.2-34.7)     0.000

  HbA1c, %                   6.0(5.1-6.4)      7.7(6.5-13.3)      0.000
  -------------------------------------------------------------------------

BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HR, heart rate; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; WHR, waist-hip ratio; 2h-PG, 2-hour plasma glucose. \* adjusted by age, body weight, current smoking.
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